Cardiff Oncology: Fourth Quarter Financial Results Overview

Cardiff Oncology Announces Fourth Quarter Financial Results

Cardiff Oncology, Inc., headquartered in San Diego, disclosed a fourth-quarter net loss of $7.2 million.

According to the company, this equates to a loss of 11 cents per share.

Despite the loss, the figures were better than anticipated by Wall Street analysts. Six experts polled by Zacks Investment Research had predicted a loss of 18 cents per share.

The molecular diagnostics firm generated $243,000 in revenue during the quarter, surpassing the consensus estimate of $130,000 from four Zacks analysts.

For the full year, Cardiff Oncology reported a total loss of $45.9 million, or 69 cents per share, with annual revenue reaching $593,000.